Samir Kaul

Samir is a Founding Partner and Managing Director at Khosla Ventures, where he focuses on health, sustainability, food, and advanced technology investments. Samir led the firm’s investments in Editas Medicine [NASDAQ: EDIT], EtaGen, Guardant Health [NASDAQ: GH], Impossible Foods, Nutanix [NASDAQ: NTNX], Oscar, Pymetrics, and View, among others. 

Prior to co-founding Khosla Ventures, Samir spent five years at Flagship Ventures where he started and invested in early-stage biotechnology companies. While there, he was involved in co-founding Helicos BioSciences [IPO], a leader in developing single-molecule sequencing instruments to revolutionize personalized medicine, along with Stan Lapidus and Steve Quake of Stanford. Samir was also founding CEO of Codon Devices, where he raised their series A financing, built the technical and advisory teams, and booked significant revenues in the company’s first year of operations. His other investments include Epitome [acquired by Millipore], LS9 [acquired by REG] and Morphotek [acquired by Eisai]. 

Previously, Samir led the Arabidopsis Genome Initiative at Craig Venter’s Institute for Genomic Research. Under his direction, the project was completed early and cost-efficiently, culminating in a historic publication in the scientific journal Nature in December 2000.

Samir is active in philanthropy and has been a longstanding member of the leadership committee of the Tipping Point Community and a board member of UCSF Benioff Children’s Hospital. He holds a bachelor’s degree in biology from the University of Michigan, where he also studied biochemistry, specifically gene regulation and expression. He also holds a master’s degree in business administration from Harvard University. 

In his spare time, Samir enjoys golf, skiing, tennis, meditation, reading and traveling. He is an avid sports fan with undying loyalty to the Michigan Wolverines, Washington Redskins and Boston Red Sox.

Read More